Compumedics (ASX:CMP) said the US Food and Drug Administration cleared the Falcon home sleep testing device to be marketed in the US, according to a Wednesday Australian bourse filing.

The device will complement the firm's Somfit technology platform. Initial sales of the platform in the last six months were around AU$1 million.

The firm is currently targeting to achieve between 10% and 30% of the addressable market over the next 24 months.

Compumedics reaffirmed its guidance for the current fiscal year of revenues of at least AU$55 million and earnings before interest, taxes, depreciation, and amortization of about AU$5 million.